{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-24-000010","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.764553+00:00","generated_at":"2026-06-06T01:15:31.907027+00:00","sec_items":["2.02","2.05","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aurinia reports 2023 net product revenue up 53% to $158.5M; ends strategic review, initiates $150M buyback","bullets":["Net product revenue $158.5M (+53% YoY); net loss $78.0M ($0.54/shr) vs $108.2M loss in 2022.","Discontinues AUR200/AUR300 development; expects $11-15M Q1'24 charge and $50-55M annual savings; headcount cut ≥25% (non-commercial).","Board authorizes up to $150M share repurchase; max subject to Canadian regulatory approval; purchases start Feb 21, 2024.","Strategic review concluded after engaging 60+ parties; one non-binding expression of interest did not lead to formal offer.","Reaffirms 2024 net product revenue guidance of $200-220M; 2,066 patients on LUPKYNIS at year-end (vs 1,525)."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-24-000010","json":"https://secwatch.observer/filing/0001600620-24-000010.json","markdown":"https://secwatch.observer/filing/0001600620-24-000010.md","text":"https://secwatch.observer/filing/0001600620-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/0001600620-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/auph-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:15:31.907027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dee582f349edd4ec85c1bef966cc91895534d048","claim":"Aurinia Pharmaceuticals Inc. updated its quarter and year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 15, 2024, Aurinia Pharmaceuticals Inc. (Aurinia) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/0001600620-24-000010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b3dd5a840cfd1e1c88d8b807ea99a76f1898f12a","claim":"Aurinia Pharmaceuticals Inc. announced a restructuring with charges of approximately $11 - $15 million affecting AUR200 and AUR300 research and development programs.","evidence_excerpt":"This will result in a one-time charge in the first quarter of 2024 of approximately $11 - $15 million and expected operational cost savings of approximately $50 - $55 million annually, with approximately 75% being recognized in 2024 excluding the one-time restructuring charge in the first quarter of 2024.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/0001600620-24-000010-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $11 - $15 million"},{"label":"Affected area","value":"AUR200 and AUR300 research and development programs"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}